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To date, attempts to eliminate HIV-1 infection from its latent reservoirs, a prerequisite for the development of a curative treatment strategy
for HIV-1 infection, have been unsuccessful. We demonstrate that the FDA approved antifungal agent amphotericin B efficiently reactivates
HIV-1 infection in THP89GFP cells, a model of HIV-1 latency in macrophages. Although amphotericin B does not directly reactivate latent
HIV-1 infection in T cells (e.g., J89GFP), amphotericin-B-stimulated macrophages (THP89GFP cells or primary macrophages) when
cocultured with J89GFP cells can induce HIV-1 reactivation in these cells in trans. Because of the close proximity of antigen presenting
macrophages and T cells in the primary lymphoid organs, such interaction between antigen presenting macrophages and T cells are frequent,
and it seems reasonable to assume that trans-reactivation strategies hold promise to also reactivate latent HIV-1 infection in vivo.
D 2004 Elsevier Inc. All rights reserved.
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While efficiently suppressing HIV-1 replication, highly
active antiretroviral therapy (HAART) cannot eradicate the
virus from infected patients (Chun et al., 1999a, 2000;
Davey et al., 1999; Wong et al., 1997). Present HIV-1
therapy would thus require a life-long treatment, which is
hampered by drug side effects, development of drug
resistant virus strains, and high treatment costs. In this
setting, the development of a curative treatment strategy
with the goal to eradicate HIV-1 from the infected patients is
a major challenge. An essential step towards this goal is the
depletion of the viral reservoirs in latently infected cells.
According to the present understanding, HIV-1 latency
develops primarily in memory T cells and macrophages
(Chun et al., 1997a, 1997b, 1998; Crowe and Sonza, 2000;
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reactivation of latent HIV-1 infection in both cell types can
be achieved by a variety of physiological stimuli, such as
TNF-a, IL-1h, IL-2 IL-6, IFN-g, or CD154 (Biswas et al.,
1992; Butera et al., 1991; Duh et al., 1989; Folks et al.,
1987; Kutsch et al., 2003; Poli et al., 1994). Chemical
compounds that reactivate latent HIV-1 infection, among
others, are the phorbol esters PMA (Folks et al., 1988) and
prostratin (Korin et al., 2002; Kulkosky et al., 2001), and the
histone deacetylase inhibitor trichostatin A (TSA) (Quivy et
al., 2002; Sheridan et al., 1997; Van Lint et al., 1996) and
sodium butyrate (Laughlin et al., 1993, 1995). In addition,
certain activating antibodies can mediate HIV-1 reactivation
(anti-CD3) (Tong-Starkesen et al., 1989; Wong et al., 1997).
Although these stimuli efficiently reactivate latent HIV-1
infection in vitro, severe side effects prevent their usage in
vivo. To date, only IL-2 and anti-CD3 antibodies have been
used in small clinical trials. However, initial studies in
patients have shown no meaningful decay of the viral latent
reservoir but significant adverse side effects (Chun et al.,
1999b; Dybul et al., 2002; Kovacs et al., 2000, 2001;
Kulkosky et al., 2002).05) 106–116
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compounds with HIV-1 reactivating properties, we have
recently established a cell-based reporter system that allows
direct quantification of HIV-1 reactivation on a single cell
basis, using EGFP as a read-out (Kutsch et al., 2002). The
system consists of the monocytic THP89GFP cells and two
T cell lines, J89GFP and JNLGFP, which contain an
integrated but transcriptionally silent copy of molecular
clones of HIV-1 89.6 and HIV-1 NL4-3, respectively,
engineered to express EGFP.
In this study, we used these cell lines to study the effect of
amphotericin B, an FDA-approved antifungal agent, on latent
HIV-1 infection. Amphotericin B is the treatment of choice
for a variety of mycoses and is used in the treatment of fungal
infections in AIDS patients (Coker et al., 1993; Hsieh et al.,
1998;Marty andMylonakis, 2002;McKinsey et al., 1989). In
vitro, amphotericin B and its derivate MS-8209 have been
reported to induce TNF-a expression in macrophages and to
increase HIV-1 expression in acutely infected macrophages
(Chia and Pollack, 1989; Clayette et al., 2000; Tokuda et al.,
1993). Other reports demonstrated that amphotericin B and
its derivate MS-8209 have anti-HIV-1 properties, inhibiting
viral replication in Tcells in in vitro experiments (Cefai et al.,
1991; Hansen et al., 1990; Konopka et al., 1999; Otake et al.,
1989; Pleskoff et al., 1995, 1996; Pontani et al., 1989a,
1989b; Schaffner et al., 1986).
Here, we report the ability of amphotericin B to reactivate
latent HIV-1 infection. Low doses of amphotericin B are
sufficient to directly reactivate latent HIV-1 infection in the
monocytic cell line THP89GFP. Although amphotericin B
did not directly reactivate latent HIV-1 infection in T cells
(J89GFP cells), cocultures of amphotericin-B-stimulated
THP89GFP cells or primary macrophages with J89GFP cells
were able to trigger HIV-1 reactivation in J89GFP in trans.
In vivo, such a btrans-reactivationQ approach would
exploit the frequent immunological interaction of T cells
and macrophages during antigen presentation. Specific
activation of macrophages could directly reactivate latent
HIV-1 in macrophages, which upon cell-to-cell contact
trigger reactivation of latent HIV-1 in T cells.
This approach, here exemplified by the use of amphoter-
icin B, adds to the strategies that should be further
investigated as an alternative approach to eradicate the pool
of latent HIV-1 from infected patients.Results
Amphotericin-B-mediated reactivation of latent HIV-1
infection
It is an accepted concept that specific activation of cells
harboring latent HIV-1 can result in reactivation of HIV-1
infection. Unfortunately, presently no FDA approved drugs
are described that could be used for this purpose. As
amphotericin B, a potent approved antifungal drug, haspreviously been described to activate macrophages, we
thought to determine the effect of amphotericin B on latent
HIV-1 infection in THP89GFP cells, a model for latently
infected macrophages, and the latently infected T cell lines
J89GFP and JNLGFP.
Treatment of the latently infected T cell lines J89GFP and
JNLGFP with amphotericin B did not result in reactivation
of latent HIV-1 infection. However, HIV-1 reactivation in
THP89GFP cells was seen at amphotericin B concentrations
as low as 0.3 Ag/ml. Near-complete reactivation of HIV-1
infection in THP89GFP cells on a population level was
achieved at an amphotericin B concentration of 3 Ag/ml. At
a concentration of 10 Ag/ml of amphotericin B, levels of
HIV-1 expression measured as EGFP mean channel
fluorescence were comparable to those seen following
stimulation with TNF-a (10 ng/ml) (Fig. 1). As seen
following stimulation with TNF-a, amphotericin-B-medi-
ated HIV-1 reactivation was accompanied by a pronounced
increase in the cell surface expression of ICAM-1, but in
contrast to stimulation with IFN-g, no induction of MHC
class II expression was seen, suggesting that amphotericin B
exerts its function mostly by activating the NF-nB pathway
(Fig. 2).
Augmentation of amphotericin B triggered HIV-1
reactivation in THP89GFP cells by autocrine secreted
TNF-a
It has been previously reported that stimulation of macro-
phages with amphotericin B results in TNF-a secretion,
which in turn could contribute to HIV-1 reactivation (Chia
and Pollack, 1989; Tokuda et al., 1993). TNF-a secretion
frommacrophages following stimulation has been reported to
be controlled by the ERK MAPK pathway (Andersson and
Sundler, 2000; Pearson et al., 2001; Suttles et al., 1999). To
investigate the possible contribution of TNF-a secretion to
amphotericin-B-mediated HIV-1 reactivation in THP89GFP
cells, we thus pretreated the cells for 1 h with various
concentrations of the specific ERK inhibitor U0126 (0.01–1
AM), or the inactive control compound UO124 (1 AM), and
then stimulated the cells with amphotericin B (10 Ag/ml).
Levels of TNF-a in the culture supernatants were determined
by ELISA and compared to levels of HIV-1 expression in
THP89GFP cells, as measured by flow cytometry. 50 pg/ml
TNF-a were detected in the supernatants of unstimulated
THP89GFP cells. Forty-eight hours after stimulation, TNF-a
levels in cultures treated with amphotericin B alone were
increased to 300 pg/ml. Addition of increasing amounts of
U0126 (0.1–1.0 AM) gradually inhibited TNF-a secretion to
baseline levels but had no effect on EGFP fluorescence as a
marker of HIV-1 expression, indicating that the presence of
TNF-a in the supernatants is mostly augmenting HIV-1
expression but is not necessary to trigger HIV-1 reactivation.
Higher concentrations of U0126 also affected the levels of
HIV-1 reactivation. As concentrations of U0126 up to 10 AM
did not alter the viability of the cells, this suggests that the
Fig. 1. Amphotericin-B-mediated reactivation of latent HIV-1 infection in THP89GFP cells. J89GFP and THP89GFP cells, respectively, were left untreated (A
and D), stimulated with amphotericin B (10 Ag/ml) (B and E), or as a positive control stimulated with TNF-a (10 ng/ml) (C and F) and EGFP fluorescence as a
marker of HIV-1 expression was determined by flow cytometry after 48 h. Quantification of HIV-1 reactivation as indicated by EGFP expression determined as
(G) the percentage of EGFP-positive cells or (H) the EGFP mean channel fluorescence intensity of the treated cell population. Results represent the meanF SD
of three independent experiments.
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triggered signaling cascade in THP89GFP cells (Fig. 3). With
respect to inhibition of HIV-1 reactivation, similar results
were obtained when THP89GFP cells were stimulated with
amphotericin B in the presence of neutralizing anti-TNF-a
antibodies (Fig. 3B). These results suggest that amphotericin
B triggers HIV-1 reactivation in a TNF-a independent
manner, but the secreted TNF-a then augments virus
expression.
Trans-reactivation of latent HIV-1 in J89GFP T cells
Although amphotericin B did not directly induce HIV-1
reactivation in latently infected T cells (J89GFP), we
investigated the possibility that factors secreted by ampho-
tericin-B-stimulated monocyte/macrophages (THP89GFP
cells, primary macrophages) could reactivate latent HIV-1
in bystander T cells (J89GFP). Forty-eight hours followingamphotericin B stimulation of THP89GFP cells (1.0–10 Ag/
ml), we conducted supernatant transfer experiments using
the latently HIV-1-infected reporter cell line J89GFP.
Despite the demonstrated presence of TNF-a, supernatants
from THP89GFP cultures stimulated with amphotericin B
concentrations as high as 10 Ag/ml did not, or only slightly
triggered, HIV-1 reactivation in J89GFP cells (12% EGFP-
positive cells at 48 h; data not shown). A possible
explanation for this finding is that the secreted TNF-a is
mostly bound and functionally neutralized by secreted
soluble TNF-receptor (sTNFR). To test this hypothesis, we
used supernatants from the cultures of THP89GFP cells
stimulated with 10Ag/ml of amphotericin B. We then treated
samples of these culture supernatants with anti-TNFR I- or
TNFR II-specific neutralizing antibodies that recognize the
respective TNF-a binding side. As these antibodies have a
much higher affinity to the respective TNFRs than TNF-a,
bound TNF-a is released from the TNFR/TNF-a complexes
Fig. 2. Correlation of cellular and viral activation in THP89GFP. The effects of amphotericin B (10 Ag/ml), TNF-a (10 ng/ml; NF-nB-dependent activation), and
IFN-g (500 U/ml; NF-nB independent activation) on the macrophage activation marker MHC class II (MHC II) and ICAM-1 and on HIV-1 infection (EGFP)
were assessed 48 h following stimulation with optimal concentrations of the respective agent. The results are representative for two independent experiments.
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of the antibody-TNFR complexes by protein G sepharose
precipitation, we used these supernatants and the corre-
sponding original untreated supernatants to determine the
amount of free TNF-a. We found that the majority of the
secreted TNF-a is indeed bound to either sTNFRI or
sTNFRII. At the 12-h time point, which would be relevant
for TNF-a-mediated reactivation at a later 24- or 48-h timeFig. 3. Amphotericin B triggers HIV-1 reactivation independent of autocrine TNF
with various concentrations of the ERK-inhibitor U0126 or the inactive control com
eight hours after amphotericin B stimulation, levels of HIV-1 reactivation were asse
and compared to the levels of TNF-a expression as determined by ELISA (dar
experiments. (B) Neutralizing anti-TNF-a antibody was added to THP89GFP cells
amphotericin B (10 Ag/ml), and 48 h poststimulation levels of HIV-1 reactivation
channel fluorescence. The results represent the mean F SD of three independentpoint, only 200 pg/ml of free TNF-a could be detected in
the cultures, which is insufficient to fully reactivate latent
HIV-1 in J89GFP cells, whereas 400 pg/ml were function-
ally neutralized by sTNFR (Fig. 4) (Kutsch et al., 2002). At
the 48-h time point, still more than 60% of TNF-a was
TNFR-bound and thus functionally neutralized, suggesting
that TNF-a activity would be very local and mostly
restricted to cell-to-cell contact.-a secretion. (A) THP89GFP cells were left untreated or for 2 h pretreated
pound U0124, and then stimulated with amphotericin B (10 Ag/ml). Forty-
ssed by flow cytometric determination of EGFP expression (light gray bars)
k gray bars). The results represent the mean F SD of three independent
at the various concentrations indicated. The cells were then stimulated with
were determined by flow cytometric analysis and depicted as EGFP mean
experiments.
Fig. 4. Contribution of sTNFR1 and sTNFRII to functional neutralization of
secreted TNF-a. Supernatants from THP89GFP cells treated with ampho-
tericin B (10 Ag/ml) were harvested at the indicated time points.
Supernatants were either directly applied to a TNF-a-specific ELISA or
following pretreatment with neutralizing anti-TNFRI or anti-TNFRII
antibody. Due to their extremely high affinity, these antibodies release
TNF-a bound to the respective TNFR and thus allow for the determination
of the level of receptor bound TNF-a. (A) Levels of free TNF-a compared
to the levels of TNF-a bound to TNFRI or TNFRII. (B) Levels of total
receptor-bound TNF-a in comparison to total TNF-a. The results represent
the mean F SD of three independent experiments.
J. Jones et al. / Virology 331 (2005) 106–116110Indeed, while supernatant transfer experiments had little
effect on HIV-1 infection in J89GFP cells, latent HIV-1
infection in J89GFP cells was reactivated if the cells were
cocultured with amphotericin-B-stimulated THP89GFP
cells or noninfected primary human macrophages. For these
experiments, we labeled THP89GFP cells with the red-
fluorescent live-dye PKH26 and cocultured the stained cells
with J89GFP cells. Due to the uniform red fluorescence
signal of the PKH26 stained THP89GFP cells, the mono-
cytes can be distinguished from the unstained J89GFP cells
in the second fluorescence using flow cytometric analysis.
Latent HIV-1 infection in J89GFP cells cocultured treated
with THP89GFP cells was efficiently reactivated in the
presence 10 Ag/ml of amphotericin B. Again, addition of
neutralizing anti-TNF-a antibody did only slightly alter thepercentage of THP89GFP cells that exhibited reactivated
HIV-1 expression, but decreased the level of EGFP MCF in
these cells by 50%. At the same time, reactivation of latent
HIV-1 in the J89GFP cells was abrogated in the presence of
anti-TNF-a antibodies in these cultures, demonstrating that
the trans-reactivating effect here was entirely dependent on
the presence of TNF-a (Fig. 5).
Similar results were obtained using primary macro-
phages. Coculture of primary macrophages with J89GFP
cells already revealed slightly elevated levels of reactivation
in J89GFP cells in the absence of amphotericin B
stimulation (15% EGFP-positive cells). Stimulation of the
cocultures resulted in efficient reactivation of latent HIV-1
infection in the entire J89GFP population. Addition of
neutralizing anti-TNF-a antibody to these cocultures greatly
decreased the EGFP MCF in J89GFP cells, demonstrating
the contribution of TNF-a to the observed HIV-1 reactiva-
tion, but did not alter the level of EGFP-positive cells,
indicating that in this case also other factors may be
involved in HIV-1 reactivation.
Influence of amiloride on amphotericin-B-mediated HIV-1
reactivation in THP89GFP cells
At this time, very little is known about the mechanism
and signal transduction events associated with amphotericin
B treatment. However, several reports indicate that amilor-
ide, which at low concentrations acts as a potent and specific
inhibitor of transmembrane Na+ entry and Na+, K+-ATPase
at higher concentrations, blocks the Na+/H+ exchange
pathway and can counteract the effect of amphotericin B
in vitro and in vivo. We thus pretreated THP89GFP cells for
2 h with various concentrations of amiloride (3–300 AM)
and then stimulated the cells with a suboptimal concen-
tration of amphotericin B (3 Ag/ml). EGFP fluorescence as a
marker of HIV-1 expression was assessed 48 h poststimu-
lation using flow cytometric analysis. Whereas low con-
centrations of amiloride (3–10 AM) exerted no effect on
amphotericin-B-mediated HIV-1 reactivation, we found that
higher concentrations (100–300 AM) decreased the level of
HIV-1 reactivation on a population basis by 40% (Fig. 6). At
the same time, amiloride had no influence on the level of
EGFP fluorescence intensity in the cells with active HIV-1
expression. This finding suggests that alteration of the
intracellular ion concentrations, in particular the intracellular
pH, may play a role in the observed amphotericin-B-
mediated HIV-1 reactivation (Makutonina et al., 1996).Discussion
In the course of an HIV-1 infection, macrophages are
among the first cells to be exposed to the virus (Meltzer and
Gendelman, 1992; Meltzer et al., 1990) and later on provide
a reservoir for HIV-1 in the lower body as well as in the
brain (Bagasra et al., 1996; Clements et al., 2002; Demuth et
Fig. 5. Trans-reactivation of latent HIV-1 infection in T cells. To allow for analytical separation using flow cytometry, THP89GFP were stained with PKH26
and then cocultured with J89GFP cells for 48 h. (A) Cultures were left unstimulated, (B) treated with amphotericin B (10 Ag/ml), or (C) stimulated with
amphotericin B in the presence of neutralizing anti-TNF-a antibody. Levels of HIV-1 reactivation under the respective culture conditions were determined by
flow cytometric analysis of EGFP expression. Numbers indicate the percentage of cells in each quadrant and the EGFP mean channel fluorescence (MCF).
J89GFP cells were cocultured for 48 h with primary macrophages that were differentiated for 5 days in tissue culture. Cultures were (D) left unstimulated, (E)
stimulated with amphotericin B, or (F) amphotericin B treated in the presence of neutralizing anti-TNF-a antibody. Levels of HIV-1 reactivation observed in
J89GFP cells were determined by flow cytometry (EGFP). Numbers indicate the percentage of EGFP-positive cells and the EGFP MCF. The results are
representative for three independent experiments.
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ongoing HIV-1 infection has recently been demonstrated in
a rhesus monkey/SHIV model (Igarashi et al., 2001), where
following systemic depletion of the CD4+ T cell pool that
usually sustains virus replication, viremia persisted at levels
of 106–107 RNA copies/ml. This persistence was apparentlyFig. 6. Influence of amiloride on amphotericin-B-mediated HIV-1 reactivation in TH
with various concentrations of amiloride (0–300 AM) and then, where indicated (+
Forty-eight hours poststimulation, levels of EGFP fluorescence were assessed by fl
cells in the culture. The results represent the mean F SD of three independent ex
untreated as negative controls were treated with a combination of amiloride (Ami; 1
(3 Ag/ml). Forward scatter/side scatter (FSC/SSC) dot plots allow to assess the lev
EGFP dot plots allow to directly determine the level of active HIV-1 expression imaintained by infected tissue macrophages in the lymph
nodes, spleen, gastrointestinal tract, liver, and kidney. Due
to the reported long half-life of macrophages (Spector and
Ryan, 1969), the noncytopathic nature of HIV-1 infection in
macrophages (Meltzer and Gendelman, 1992; Meltzer et al.,
1990; Orenstein et al., 1997), and the relative insensitivity ofP89GFP cells. (A) THP89GFP cells were left untreated or pretreated for 2 h
), stimulated with a suboptimal concentration of amphotericin B (3 Ag/ml).
ow cytometric analysis and are depicted as the percentage of EGFP-positive
periments. (B) Flow cytometric analysis of THP89GFP cells that remained
00 AM) and amphotericin B (AmpB; 3 Ag/ml), or with amphotericin B alone
el of cell viability (cells in the live gate R1), whereas propidium iodide (PI)/
n the viable THP89GFP cell population.
J. Jones et al. / Virology 331 (2005) 106–116112macrophages to HIV-1 protease inhibitors (Perno et al.,
1998), these cells can propel infection for an extended
period of time, eventually even in the presence of
antiretroviral therapy. In addition, alveolar macrophages
have early on been demonstrated to harbor integrated but
transcriptionally silent viral genomes that can be reactivated
to produce infectious virus (Lebargy et al., 1994). The
possibility that HIV-1 latency can occur in macrophages and
may not be limited to memory T cells is further supported by
the genotypic discordance between rebounding virus that
can be isolated if HAART is halted and HIV-1 isolated from
the memory T cell pool (Zhang et al., 2000). Also, the
kinetics of virus proliferation following therapy cessation
cannot be explained under the assumption that latently
infected memory T cells are the sole source of virus (Chun
et al., 2000; Davey et al., 1999).
Unfortunately, the precise contribution of infected
macrophages to the pool of latently infected cells is
difficult to assess. Macrophages, which are readily
accessible in the peripheral blood or the lymph nodes,
per definition must be activated and should not harbor
latent virus, whereas resting macrophages that reside in
the body tissues or the brain are usually not accessible
for experimental purposes. Irrespective of whether HIV-1
infection in macrophages persists in a latent state or
simply in a state of very low level transcriptional activity,
novel means to activate infection are required to
efficiently target and deplete these cells.
To this end, we here demonstrate that the FDA approved
antifungal agent amphotericin B efficiently reactivates latent
HIV-1 infection in THP89GFP cells, a model for HIV-1
latency in macrophages (Kutsch et al., 2002, 2003). In
contrast, no activating effect of amphotericin B on latent
HIV-1 was seen in a T cell model of HIV-1 latency (J89GFP
and JNLGFP cells) (Kutsch et al., 2002).
Nevertheless, amphotericin-B-mediated HIV-1 reactiva-
tion in T cells could be achieved in trans in cocultures of
J89GFP cells with either THP89GFP cells or primary
macrophages. In the case of J89GFP/THP89GFP cocultures,
the trans-reactivating effect was apparently mostly depend-
ent on membrane bound TNF-a, as addition of neutralizing
anti-TNF-a antibodies abrogated HIV-1 reactivation in the T
cell line, while supernatant transfer from amphotericin-B-
stimulated THP89GFP cells to J89GFP cells did not result
in HIV-1 reactivation. In cocultures of J89GFP cells with
primary macrophages, HIV-1 reactivation was only partially
mediated by amphotericin-B-stimulated TNF-a secretion, as
even addition of high concentrations of neutralizing anti-
TNF-a antibody to the cocultures could only decrease the
level of HIV-1 expression in J89GFP cells, but did not
inhibit reactivation on a population level. As we were not
able to specify a second soluble factor contributing to HIV-1
reactivation in J89GFP cells in cocultures with primary
macrophages, we speculate that interaction of costimulatory
receptors such as B7 on the macrophage site and CD28 on
J89GFP cells may play a role.The approach to target latent HIV-1 infection in T cells in
trans by activating antigen-presenting cells that confer the
reactivation trigger upon cell-to-cell contact adds to the
strategies that may be employed to deplete HIV-1 from its
latent reservoirs in patients. In addition, activation of
potentially existing low-level viral replication in macro-
phages may also allow for eradication of these cells
following immune recognition or would improve the ability
of HIV-1-specific immunotoxins to target these cells
(Chaudhary et al., 1988; Hamer et al., 2003; McHugh et
al., 2002; Root and Hamer, 2003).
Agents such as amphotericin B and its derivate MS-8209
would be particularly suited for this task, as they activate
latent or low-level HIV-1 expression, but at the same time
have been described to inhibit HIV-1 replication in T cells
(Cefai et al., 1991; Otake et al., 1991; Pontani et al., 1989a;
Schaffner et al., 1986). However, very little is known how
amphotericin B actually exerts its activity in macrophages.
It has been reported that amphotericin B complexes
membrane cholesterol and increases potassium efflux.
However, we demonstrate that amiloride, which at the
experimental concentrations used is known to block the
Na+/H+ exchange pathway, specifically counteracts the HIV-
1 reactivating effect of amphotericin B. Although these data
suggest that intracellular K+, Na+, or H+ concentrations may
actually play a significant role in the observed amphotericin
B effect on latent HIV-1, and indeed it has previously been
shown that HIV-1 infection induces changes in intracellular
K+, Na+, or H+ concentrations (Makutonina et al., 1996;
Voss et al., 1996a,b), the data do not allow to draw any
conclusion whether changes in the intracellular ion milieu
are triggering virus replication or are simply required to
maintain viral expression.
Clearly, high-dose amphotericin B treatment as admin-
istered, for example, for systemic candidosis, is associated
with a variety of side effects. These are usually transient in
nature, and McKinsey et al. (1989) have demonstrated that
even long-term amphotericin B treatment is rather well
tolerated in HIV-1 patients. As for cancer chemotherapy,
potential adverse side effects would have to be balanced
with the benefits of such a treatment. There are, however,
alternatives to the commonly used high-dose treatment.
Liposomal formulations of amphotericin B have demon-
strated improved tolerability in patients while maintaining
full efficacy against the respective fungal agents and the
HIV-1 inhibitory capacity of amphotericin B (Pontani et al.,
1989a; Reyes et al., 2000). Also, amphotericin B derivates
such as MS-8209 seem to be less cytotoxic and could
provide treatment alternatives (Clayette et al., 2000). In fact,
MS-8209 has been successfully used to treat various prion-
related diseases in a variety of animal models (Demaimay et
al., 1997, 1999). The ability of MS-8209 to slow down the
progress of the brain resident effects of various forms of
prion disease in animal models also points towards another
major consideration for successful HIV-1 reactivating drugs.
As HIV-1-infected macrophages have also been detected in
J. Jones et al. / Virology 331 (2005) 106–116 113the brain, the compound’s ability to permeate through the
blood-brain barrier is potentially important (Clements et al.,
2002). Amphotericin B would also fulfill this requirement,
as it is commonly used to treat fungus induced forms of
meningitis (Coker et al., 1993; Guiloff and Tan, 1992; Hsieh
et al., 1998).
In summary, the presented data establish a novel strategy
to simultaneously reactivate latent HIV-1 or low-level HIV-
1 infection in macrophages and T cells. Generalized
activation of antigen presenting cells, here macrophages,
achieved in a chemotherapy-like manner, is used to convey
cell activation of T cells by cell-to-cell contact, exploiting
the basic principle of continuous immune surveillance.
Elimination of the cells harboring the previously latent HIV-
1 infection would then be assisted by the application of
suitable HIV-1-specific immunotoxins. Whether amphoter-
icin B would indeed be a suitable drug candidate for such an
endeavor and could be used to develop a treatment strategy
for HIV-1 with curative intent remains to be seen, but it
clearly possesses the required drug characteristics: (i)
capacity of inducing HIV-1 expression; (ii) capacity to
induce systemic activation of macrophages; (iii) permeates
the blood brain barrier and can thus target brain resident
reservoirs of latent HIV-1.
In a monotherapeutic approach, amphotericin B or drugs
with similar characteristics will probably not be capable of
depleting the entire pool of latently infected cells, but in
combination with, for example, low-level IL-2 treatment,
the described approach of trans-reactivation should be
seriously entertained.Materials and methods
Cell culture and reagents
THP89GFP cells and J89GFP cells were maintained in
RPMI 1640 supplemented with 2 mM l-glutamine, 100 U/
ml penicillin, 100 Ag/ml streptomycin, and 10% heat-
inactivated fetal bovine serum, as previously described
(Kutsch et al., 2002).
Macrophages were generated by plating 10  106
PBMCs/well in a 6-well plate and culturing the cells in
DMEM supplemented with 2 mM l-glutamine, 100 U/ml
penicillin, 100 Ag/ml streptomycin, 10% fetal bovine serum,
10% human serum, and 10% giant cell medium. On day 5,
the nonadherent cells were removed by several stringent
washing steps using ice-cold medium. The purity of the
obtained macrophage cultures is generally 95% or higher, as
determined by fluorescence microscope analysis following
staining for CD14.
Amphotericin B was purchased from GibcoBRL (Lang-
ley, OK). Neutralizing anti-TNF-a antibody was obtained
from Biosource (Camarillo, CA), anti-TNFR I and anti-
TNFR II from R&D Biosciences (Minneapolis, MN), and
the specific ERK inhibitor U0126 and the noninhibitorycontrol compound U0124 from Calbiochem (San Diego,
CA). The live dye PKH26 was purchased from Sigma (St.
Louis, MO).
Flow cytometric analysis
Flow cytometric analysis was performed using a FACS-
can or a FACStarPlus and CellQuest software (Becton
Dickinson). If the cells were not stained for the expression
of cell surface markers, all samples were treated with
propidium iodide to allow for the exclusion of dead cells
during data acquisition and analysis.
ELISA
Detection of human TNF-a in the culture supernatants
was performed by ELISA exactly to the manufacturer’s
instructions (Biosource). The sensitivity of the ELISA is N6
pg/ml TNF-a. To determine a potential neutralizing effect of
soluble TNF-receptor I (TNFRI) or soluble TNF-receptor II
(TNFRII), we performed antibody competition experiments.
Ten micrograms of either neutralizing anti-TNFRI or
TNFRII antibody was added to 500 Al of supernatants from
amphotericin-B-stimulated THP89GFP cells and incubated
for 1 h. As both TNF-a and the respective anti-TNFR
antibodies compete for the same binding site (epitope), the
high affinity antibody releases the receptor-bound TNF-a.
Following precipitation of the antibody-TNFR complexes
with protein G sepharose beads, the TNF-a concentration of
the supernatants was determined by ELISA. The difference
in TNF-a concentration between untreated and antibody
treated supernatants then allowed for the calculation of the
level of TNF-a bound to either soluble TNFR.Acknowledgments
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